TFT生命科学产品线

兼顾通量、产量、长度的TFT-DNA合成方案

TruSynthTM 挚合TM
寡核苷酸微阵列合成仪

世界首台基于TFT半导体技术的寡核苷酸微阵列合成仪

领挚科技融合了TFT半导体芯片技术和电化学技术的高通寡核苷酸微阵列和寡核苷酸池生产工具

TruArray® 挚睿®

寡核苷酸微阵列

TruPool® 挚璞®

寡核苷酸池

为什么选择TFT半导体?

低成本

中国大陆坐拥全球约八成TFT半导体产能,设计和工艺能力世界领先,成为TFT生命科学工具快速迭代的重要引擎

高精度

阵列密度达到细胞及亚细胞精度,完美契合单细胞和皮升至微升级分子实验需求

高通量

依托于成熟的显示技术,可轻易实现千级至千万级像素阵列

产业链优势

利用成熟制程和产能,打破“半导体芯片耗材昂贵”的刻板印象

集成化

同时完成处理和反应体系构建、反应过程控制、反应结果检测三项基本任务,使得涉及通量、载量变化的多步复杂实验流程,也能在一张芯片上完成

大面积

量产芯片可达平米级,突破硅基半导体和传统微流控芯片的载量和产能限制

TFT生物芯片三大基础能力

微阵列反应控制

适配电控、光控、温控、酶促等多种反应驱动方案,
兼顾实验通量和载量

皮升级液滴操控

实现从皮升到微升级到生物样品液滴的高通量
混合、移动、拆分等精准操作

原位信号传感

通过整合各种先进检测方案,实现高通量精准快速
灵敏的原位生物信号实时传感

打造新一代半导体生命科学工具

Dr. Kang Kang

Partner & CBio

Dr. Kang received his Ph.D. in Bioinformatics and Systems Biology from the University of Hong Kong in 2018, then became a scientific co-worker of the Leibniz Association (Leibniz-HKI) and a visiting scientist at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at the Technical University of Denmark. He was a scientist at BGI-Shenzhen and co-founded the synthetic biology research group. He was a senior bioinformatics engineer and brand advisor at WeGene. In 2021, Kang joined Biosysen Limited as a co-founder and served as Chief Informatics Scientist. He is also an advisor and author of the biotech media "Regenesis". He has been dedicated to the R&D and industrialization of OMICs technologies, high-throughput technologies, and synthetic biology for over 10 years. He joined LinkZill in March 2023, responsible for semiconductor life science tools and product planning.